JTCS Click here to go to SJM website.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Jonathan Hammond
Kenneth W. Jeleniowski
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coleman, C. I.
Right arrow Articles by White, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coleman, C. I.
Right arrow Articles by White, C. M.
Related Collections
Right arrow Cardiac - physiology
Right arrow Cardiac - other
Right arrow Coronary disease

J Thorac Cardiovasc Surg 2007;133:1547-1552
© 2007 The American Association for Thoracic Surgery

Cardiopulmonary Support and Physiology

Evaluating the safety implications of aprotinin use: The Retrospective Evaluation of Aprotinin in Cardio Thoracic Surgery (REACTS)

Craig I. Coleman, PharmDa,c, Vera T. Rigali, PharmDc, Jonathan Hammond, MDb, Jeffrey Kluger, MDa,d, Kenneth W. Jeleniowski, CCPb, C. Michael White, PharmDa,c,*

a Division of Cardiology, Hartford Hospital, Hartford, Conn
b Division of Cardiothoracic Surgery, Hartford Hospital, Hartford, Conn
c The University of Connecticut School of Pharmacy, Storrs and Farmington, Conn
d The University of Connecticut School of Medicine, Storrs and Farmington, Conn

Received for publication October 20, 2006; revisions received January 3, 2007; accepted for publication January 8, 2007.

* Address for reprints: C. Michael White, PharmD, FCCP, FCP, Director, Cardiac Pharmacology Service, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102-5037. (Email: cmwhite{at}harthosp.org).

Objectives: Aprotinin is a drug used to reduce bleeding in patients undergoing cardiothoracic surgery with cardiopulmonary bypass. A recent cohort evaluation found elevated risks of renal, cardiovascular, and cerebrovascular events when aprotinin was used. We sought to determine the impact of aprotinin on safety variables among patients receiving cardiothoracic surgery with cardiopulmonary bypass from a single US hospital that reserves aprotinin for complex surgeries and Jehovah’s Witnesses and does not utilize celite-based activated clotting time determinations.

Methods: We performed a cohort evaluation with multivariate logistic regression, including propensity score adjustment comprising patients from January 1, 2000 and December 31, 2005. We evaluated 3348 patients having cardiothoracic surgery in a single tertiary care medical center. We observed aprotinin use or lack of aprotinin in cardiothoracic surgery. The main outcome measures were odds (expressed as an odds ratio with 95% confidence interval) of developing myocardial infarction, cerebrovascular events, and renal dysfunction after cardiothoracic surgery between groups.

Results: Patients receiving aprotinin were less likely to experience a cerebrovascular event compared with control [0.65 (0.46–0.91)] and did not have an elevated odds of myocardial infarction [1.04 (0.53–2.04)] but were more likely to experience postoperative renal dysfunction [2.03 (1.37–3.01)].

Conclusions: Aprotinin was not associated with negative myocardial or cerebrovascular risks but did increase the risk of renal dysfunction. It is not known whether the renal dysfunction reflects renal damage or a transient reduction in glomerular filtration pressure.

Abbreviations and Acronyms ACT = activated clotting time; CABG = coronary artery bypass graft; CI = confidence interval; CPB = cardiopulmonary bypass; CTS = cardiothoracic surgery; MI = myocardial infarction; OR = odds ratio; RR = relative risk; TIA = transient ischemic attack




This article has been cited by other articles:


Home page
 PerfusionHome page
Y. Iwata, T. Okamura, D. Zurakowski, and R. A. Jonas
Using activated clotting time to estimate intraoperative aprotinin concentration
Perfusion, November 1, 2009; 24(6): 397 - 400.
[Abstract] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
S. A. Barnett, M. Liava'a, and P. D. Skillington
Potential for benefits of aprotinin use to outweigh risks in patients undergoing the Ross procedure
J. Thorac. Cardiovasc. Surg., July 1, 2009; 138(1): 233 - 234.
[Full Text] [PDF]

Home page
 Anesth. Analg.Home page
A. Manrique, E. H. Jooste, B. A. Kuch, S. E. Lichtenstein, V. Morell, R. Munoz, D. Ellis, and P. J. Davis
The Association of Renal Dysfunction and the Use of Aprotinin in Patients Undergoing Congenital Cardiac Surgery Requiring Cardiopulmonary Bypass
Anesth. Analg., July 1, 2009; 109(1): 45 - 52.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
A. Levrat, A. Gros, L. Rugeri, K. Inaba, B. Floccard, C. Negrier, and J.-S. David
Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma patients
Br. J. Anaesth., June 1, 2008; 100(6): 792 - 797.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2007 by The American Association for Thoracic Surgery.